AI that moves clinical trials forward
Suvoda is applying AI across the clinical trial lifecycle—to compress study startup timelines, reduce the burden on sites and sponsors, and put clearer, more actionable data in front of the people who need it. This is not AI layered onto existing processes. It’s a rethink of how trials get built and run.
How we think about AI
The clinical trial challenges our customers face haven’t changed: too much manual work, too many handoffs, too little time. What has changed is what’s now possible.
Suvoda’s AI strategy is grounded in a simple question: given what this technology can actually do now, how do we help sponsors and CROs move faster without sacrificing the quality and control that trials demand? That means building AI that works in a regulated environment—guided by domain experts, auditable at every step, and designed to amplify human judgment rather than replace it.
Our approach is organized around three outcomes.
- Accelerate RTSM (IRT) build
- Elevate clinical trial site and study sponsor experience
- Intelligent insights
From months to weeks. Study startup, reimagined.
|
|
Getting a study from project kickoff to go-live has always required significant time and manual effort. Agentic AI changes what’s possible here.
Suvoda’s suite of XD Agents automates the code generation that has historically consumed weeks of effort. Each agent handles a distinct phase of study build, and each operates under expert-in-the-loop approval—domain experts define the rules and validate the outputs, agents handle the execution.
This is possible because Suvoda’s patented platform architecture gives agents a foundation to work from, building from our low-code/no-code tooling and a shared data layer—rather than starting from scratch on every build.
Agentic RTSM is currently in early adopter phase. Expansion to eCOA, payments, and travel is underway.
Less time navigating the system. More time on the work that matters.
Sites and sponsors spend more time than they should hunting for information—checking study status, tracking patient compliance, managing routine actions across fragmented workflows. Sofia, Suvoda’s AI assistant, is built to change that.
Sofia gives users a conversational, multilingual interface to get fast answers and surface key study insights—without leaving the platform. It’s purpose built for clinical trial operations: constrained to a validated knowledge space, enforced at the study permission level, and fully auditable.
Early adopters are live with Sofia today. Coming next: more than 70 agentic capabilities that allow Sofia to take direct actions—not just answer questions—on behalf of authorized users.
Sofia is built on three principles:
Reliable |
Teachable |
Secure |
|
Purpose-built AI agents work from a validated knowledge space with independent checks to minimize the risk of inaccurate outputs. |
The knowledge base is built and maintained by Suvoda's domain experts, with instruction steps that can be validated and updated as trial needs evolve. |
Study-level permissions and data access controls are enforced throughout. Every action is logged and auditable. |
Real-time visibility into what’s actually happening in your trial.
Sponsors and CROs sitting on operational data from across their trial ecosystem rarely have it surfaced in a useful form—enrollment velocity, site performance trends, supply risk. That data exists today. AI makes it actionable in real time.
Suvoda is building toward intelligent insights that draw on operational data from your trials to support faster, better-informed decisions: where to intervene, when to escalate, what’s coming before it becomes a problem.
Longer term, Sofia is positioned to deliver monitoring, alerting, and proactive decision support across the full trial lifecycle.
Why the Suvoda Platform is built for this
Most clinical trial technology companies face a challenge applying AI: their architectures weren’t designed for it. Suvoda’s was.
Our patented Virtual Partition architecture separates the core validated product from study-specific configuration and customization—which means AI agents generate only what needs to be trial-specific, without touching validated code. The result is AI that is fast, consistent, and safe for a regulated environment.
It also means that every AI capability we build layers onto a platform that already manages RTSM, eCOA, eConsent, patient payments, travel, scheduling, and more. The data layer is unified. The agents have context. And as agentic capabilities expand, they expand across the full Suvoda Platform.
FAQs
Agentic AI refers to AI systems that can take directed actions—not just answer questions—within a defined workflow. In clinical trials, that means AI that can generate study specifications, write configuration code, produce test scripts, and surface operational insights, guided by human experts and validated at each stage.
IRT (Interactive Response Technology) and RTSM (Randomization and Trial Supply Management) refer to the same category of clinical trial software. The terms evolved separately —IRT describing how the system works (users interact with it in real time), RTSM describing what it does (manages randomization and drug supply)—but today they're used interchangeably across the industry.
Modern RTSM systems, including Suvoda RTSM, deliver all the capabilities that IRT has always provided, and more. If your team uses IRT, RTSM, or both, you're talking about the same system.
General-purpose AI tools aren’t built for the constraints of regulated clinical research. Suvoda’s AI capabilities are purpose-built: they operate within a validated knowledge space, enforce study-level permissions, produce auditable outputs, and are guided by domain experts who understand clinical trials—not just software.
Agentic RTSM is in early adopter rollout, with plans to expand broadly by Q4. Sofia is live with early adopter customers today. Additional agentic capabilities are planned for release in 2026.